By Turna Ray

The first clinical trial conducted at the newly founded Center for Comparative Effectiveness Research in Cancer Genomics, or CancerGen, will investigate the predictive ability of Genomic Health's Oncotype DX test to determine which node-positive breast cancer patients will benefit from a tamoxifen-based chemotherapy regimen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.